Inactive Instrument

Highlights Lexicon Pharmaceuticals, Inc. Nasdaq

Equities

US5288721047

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease	Mar. 12	CI
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	Mar. 11	DJ
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Jump	Mar. 11	MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell	Mar. 11	MT
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin	Mar. 11	DJ
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q4 Revenue $702,000	Mar. 11	MT
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
Lexicon Pharmaceuticals, Inc Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA	Mar. 11	CI
Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	CI
Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain	Nov. 30	CI
Lexicon Pharmaceuticals, Inc. Announces Post Hoc Analysis of Clinical Data from the SCORED Trial	Nov. 12	CI
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q3 Revenue $162,000	Nov. 08	MT
Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting	23-10-17	CI
Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients	23-10-09	CI
Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes	23-09-26	CI
Lexicon Pharmaceuticals Shares Climb After CFO Jeffrey Wade Boosts Stake	23-09-15	MT
Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure	23-08-08	CI
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q2 Revenue $317,000, vs. Street Est of $0.13M	23-08-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lexicon Pharmaceuticals, Inc. Nasdaq

Equities

US5288721047

Highlights

Filters